Hyperplasia and adenoma were more frequently observed in the DEN-treated control group, whereas hepatocellular carcinoma tumors were more predominant in the DEN-treated Parg knockout group (Figure 6B,C). The gene discussed is PARG; the disease is hepatocellular carcinoma.